Skip to main content

Table 2 Summary of clinical response in relation to KRAS mutational status.

From: Low Percentage of KRAS Mutations Revealed by Locked Nucleic Acid Polymerase Chain Reaction: Implications for Treatment of Metastatic Colorectal Cancer

  RP/RC SD PD Total
All 29 (30.5%) 37 (38.9%) 29 (30.5%) 95
WT/WT 23 (36.5%) 22 (34.9%) 18 (28.6%) 63
WT/mutated 6 (18.75%) 15 (46.85%) 11 (34.4%) 32